NVO News Today, Nov 4: Novo Nordisk Faces Legal Battle with Pfizer

Novo Nordisk, a leading player in the pharmaceutical world, is embroiled in a legal tussle with Pfizer. The controversy centers on Novo’s recent acquisition of Metsera, a burgeoning biotech specializing in obesity treatment. Pfizer claims the acquisition is anticompetitive, potentially tightening Novo’s grip on the rapidly growing obesity market. This development has significant implications for investors as the weight loss drug industry becomes more competitive.